0000885590-14-000015.txt : 20140128
0000885590-14-000015.hdr.sgml : 20140128
20140128170011
ACCESSION NUMBER: 0000885590-14-000015
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20140124
FILED AS OF DATE: 20140128
DATE AS OF CHANGE: 20140128
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Valeant Pharmaceuticals International, Inc.
CENTRAL INDEX KEY: 0000885590
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: A8
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2150 ST. ELZEAR BLVD. WEST
STREET 2: LAVAL
CITY: QUEBEC
STATE: A8
ZIP: H7L 4A8
BUSINESS PHONE: 514-744-6792
MAIL ADDRESS:
STREET 1: 2150 ST. ELZEAR BLVD. WEST
STREET 2: LAVAL
CITY: QUEBEC
STATE: A8
ZIP: H7L 4A8
FORMER COMPANY:
FORMER CONFORMED NAME: BIOVAIL Corp
DATE OF NAME CHANGE: 20100416
FORMER COMPANY:
FORMER CONFORMED NAME: BIOVAIL CORP INTERNATIONAL
DATE OF NAME CHANGE: 19960522
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mirovsky Pavel
CENTRAL INDEX KEY: 0001577638
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-14956
FILM NUMBER: 14553664
MAIL ADDRESS:
STREET 1: 2150 ST. ELZEAR BLVD. WEST
CITY: LAVAL
STATE: A8
ZIP: H7L 4A8
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2014-01-24
0
0000885590
Valeant Pharmaceuticals International, Inc.
VRX
0001577638
Mirovsky Pavel
2150 ST. ELZEAR BLVD. WEST
LAVAL
A8
H7L 4A8
QUEBEC, CANADA
0
1
0
0
President of Valeant Europe
Common Stock, no par value
2014-01-24
4
M
0
10000
0
A
10000
D
Restricted Share Units
2014-01-24
4
M
0
10000
0
D
Common Stock
10000
10000
D
This represents the number of units vested on the performance-based RSUs ("PSUs") that were previously reported on the original Form 4. The initial grant was reported to vest based on total shareholder return (TSR) between a price of $54.15 starting on May 15, 2012 and the average stock price for the 20 trading days starting on each measurement dates: 25% on February 15, 2015, 50% on May 15, 2015 and 25% on August 15, 2015. Unit vesting is contingent on TSR performance between 15% and 45% into between one and three shares of common stock, respectively, with early vesting possible at higher TSR levels. The PSU award may still payout two times grant value.
by: Nicholas Zanoni for Pavel Mirovsky
2014-01-28